With an agreement in hand to conduct research at the University of Pennsylvania's gene therapy center, as well as the expertise of scientist and company co-founder James Wilson, newly formed Passage Bio launched Thursday with a $115.5 million series A financing, money it will use toward rare monogenic central nervous system (CNS) diseases.